ESSA Pharma Inc. filings document the company's completed plan of arrangement, shareholder approval process, capital-structure treatment of common shares, options and warrants, and subsequent Form 25 removal of its common stock from Nasdaq listing and Section 12(b) registration. Form 8-K reports cover material agreements, votes of securityholders, acquisition or disposition completion, governance matters, risk factors, clinical or regulatory disclosures, and operating and financial results.
ESSA Pharma (EPIX) reported interim results as of June 30, 2025 showing a strong cash position and a major strategic shift. The company held $85.95 million in cash and $23.67 million in short-term U.S. Treasury securities, giving working capital of $108.90 million and total assets of $110.50 million. ESSA recorded a net loss of $18.91 million for the nine months ended June 30, 2025 and an accumulated deficit of $226.91 million. In October 2024 ESSA terminated clinical trials of its lead candidate, masofaniten (EPI-7386), and withdrew related IND/CTA filings. Subsequent to the quarter, ESSA entered a Business Combination Agreement with XenoTherapeutics under which shareholders are currently estimated to receive approximately US$1.91 per share plus one non-transferable contingent value right (CVR) per share entitling holders to a pro rata portion of up to US$2.95 million (up to US$0.06 per CVR). The Transaction requires court and shareholder approvals and is expected to close in the second half of 2025.
ESSA Pharma (EPIX) is asking Securityholders to approve a court‑approved Plan of Arrangement to be voted on at a virtual Special Meeting on September 10, 2025. Under the Arrangement, Xeno Acquisition Corp. (a subsidiary of XenoTherapeutics) will acquire all outstanding common shares for an estimated Cash Amount of approximately US$1.91 per share (subject to reduction by a Distribution) plus one CVR per share entitling holders to a pro‑rata portion of up to US$2,950,000 less specified deductions related to litigation and costs.
The Board and an independent Transaction Committee unanimously recommend the Arrangement and received a fairness opinion from Leerink Partners dated July 13, 2025. The Company received court authorization for a concurrent capital reduction and a proposed aggregate Distribution of US$80,000,000 (scheduled on or about August 22, 2025). As of the Record Date (August 5, 2025) there were 44,338,550 common shares outstanding, 7,830,523 Options and 2,920,000 Warrants. Closing is expected on or about September 18, 2025, after required shareholder votes and court orders, and will result in delisting from Nasdaq and deregistration under the Exchange Act.